Showing 81 - 100 results of 497 for search '"Фармакоэкономика"', query time: 0.04s Refine Results
  1. 81
    Molecular pharmacology of coenzyme Q10 in the context of treatment of hyperlipidemic conditions

    Molecular pharmacology of coenzyme Q10 in the context of treatment of hyperlipidemic conditions by O. A. Gromova, I. Yu. Torshin

    Published 2023-07-01
    “…Фармакоэкономика…”
    Get full text
    Article
    Save to List
    Saved in:
  2. 82
    Clamorous denial of “clamorous denial”: much ado... about nothing?

    Clamorous denial of “clamorous denial”: much ado... about nothing? by O. A. Gromova, Zh. D. Kobalava, I. Yu. Torshin

    Published 2020-04-01
    “…Фармакоэкономика…”
    Get full text
    Article
    Save to List
    Saved in:
  3. 83
    Systematic analysis of molecules regulating nitric oxide (NO) metabolism and vascular endothelium condition

    Systematic analysis of molecules regulating nitric oxide (NO) metabolism and vascular endothelium condition by I. Yu. Torshin, A. G. Chuchalin, O. A. Gromova

    Published 2025-05-01
    “…Фармакоэкономика…”
    Get full text
    Article
    Save to List
    Saved in:
  4. 84
    History of controlled trials in medicine: real priorities are little-known. Report 2. From early experiments to the present day: without alternation and randomization

    History of controlled trials in medicine: real priorities are little-known. Report 2. From early experiments to the present day: without alternation and randomization by A. N. Koterov, O. A. Tikhonova, L. N. Ushenkova, A. P. Biryukov

    Published 2021-10-01
    “…Фармакоэкономика…”
    Get full text
    Article
    Save to List
    Saved in:
  5. 85
    ECONOMIC ASSESSMENT OF MAGNESIUM DEFICIENCY CORRECTION FOR BASIC THERAPY EFFICACY OF UNCONTROLLED ASTHMA IN CHILDREN

    ECONOMIC ASSESSMENT OF MAGNESIUM DEFICIENCY CORRECTION FOR BASIC THERAPY EFFICACY OF UNCONTROLLED ASTHMA IN CHILDREN by V. I. Petrov, I. N. Shishimorov, O. V. Magnitskaya, Ju. V. Ponomareva

    Published 2015-03-01
    “…Фармакоэкономика…”
    Get full text
    Article
    Save to List
    Saved in:
  6. 86
    ROLE OF RANDOMIZED TRIALS IN PHARMACOEPIDEMIOLOGY

    ROLE OF RANDOMIZED TRIALS IN PHARMACOEPIDEMIOLOGY by T. L. Galankin, A. S. Kolbin

    Published 2015-03-01
    “…Фармакоэкономика…”
    Get full text
    Article
    Save to List
    Saved in:
  7. 87
    Comparative clinical and economic analysis of using SYSADOA drugs containing chondroitin sulphate or influencing its biosynthesis in the treatment of patients with stage II knee osteoarthritis

    Comparative clinical and economic analysis of using SYSADOA drugs containing chondroitin sulphate or influencing its biosynthesis in the treatment of patients with stage II knee os... by I. V. Sarvilina, A. N. Galustyan, A. K. Hadzhidis, I. S. Sardaryan, N. V. Lavrov, O. A. Gromova, Yu. S. Prokofieva

    Published 2020-02-01
    “…Фармакоэкономика…”
    Get full text
    Article
    Save to List
    Saved in:
  8. 88
    Diagnosis-related groups and payments for the treatment of malignant neoplasms in the model of 2019

    Diagnosis-related groups and payments for the treatment of malignant neoplasms in the model of 2019 by D. V. Fedyaev, V. V. Omelyanovskiy, M. L. Lazareva, Yu. V. Seryapina, Yu. A. Ledovskikh

    Published 2019-10-01
    “…Фармакоэкономика…”
    Get full text
    Article
    Save to List
    Saved in:
  9. 89
    BIOLOGICAL THERAPY IN ADULT PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE: BUDGET IMPACT ANALYSIS

    BIOLOGICAL THERAPY IN ADULT PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE: BUDGET IMPACT ANALYSIS by E. A. Pyadushkina

    Published 2017-05-01
    “…Фармакоэкономика…”
    Get full text
    Article
    Save to List
    Saved in:
  10. 90
    The review of the foreign experience on the financing of innovative medical technologies

    The review of the foreign experience on the financing of innovative medical technologies by V. V. Omelyanovskiy, I. A. Zheleznyakova, T. P. Bezdenezhnykh, M. L. Lazareva, D. V. Fedyaev

    Published 2020-11-01
    “…Фармакоэкономика…”
    Get full text
    Article
    Save to List
    Saved in:
  11. 91
    Regional aspects of availability of expectorants and antitussive drugs

    Regional aspects of availability of expectorants and antitussive drugs by V. М. Timiryanova, А. V. Samorodov, Z. А. Valiullina, V. B. Prudnikov, D. Kh. Krasnoselskaya

    Published 2025-02-01
    “…Фармакоэкономика…”
    Get full text
    Article
    Save to List
    Saved in:
  12. 92
    RATIONALE FOR THE SYSTEM OF INDICATORS, INTENDED FOR THE EVALUATION OF INVESTMENT EFFECTIVENESS IN THE FINANCING OF INVESTMENT PROJECTS IMPLEMENTED USING THE FUNDS OF THE POPULATION

    RATIONALE FOR THE SYSTEM OF INDICATORS, INTENDED FOR THE EVALUATION OF INVESTMENT EFFECTIVENESS IN THE FINANCING OF INVESTMENT PROJECTS IMPLEMENTED USING THE FUNDS OF THE POPULATIO... by E. V. Litvinenko

    Published 2015-03-01
    “…Фармакоэкономика…”
    Get full text
    Article
    Save to List
    Saved in:
  13. 93
    Determination of a willingness-to-pay threshold and decision-making in financing the healthcare technologies

    Determination of a willingness-to-pay threshold and decision-making in financing the healthcare technologies by T. S. Teptsova, T. P. Bezdenezhnyh, V. K. Fedyaeva, N. Z Musina, G. R. Hachatryan, V. V. Tarasov

    Published 2018-11-01
    “…Фармакоэкономика…”
    Get full text
    Article
    Save to List
    Saved in:
  14. 94
    Pharmacoeconomic analysis of antiretroviral therapy regimes in the Syrian Arab Republic

    Pharmacoeconomic analysis of antiretroviral therapy regimes in the Syrian Arab Republic by Yu. Sh. Gushchina, А. Yu. Abramov, Y. J. Haitham

    Published 2023-07-01
    “…Фармакоэкономика…”
    Get full text
    Article
    Save to List
    Saved in:
  15. 95
    MODERNIZATION OF THE MEDICAL SERVICES MARKET

    MODERNIZATION OF THE MEDICAL SERVICES MARKET by A. U. Kulikov

    Published 2015-03-01
    “…Фармакоэкономика…”
    Get full text
    Article
    Save to List
    Saved in:
  16. 96
    Treatment of patients with malignant lymphoproliferative diseases in the Russian Federation: analysis of the data from 75 regions

    Treatment of patients with malignant lymphoproliferative diseases in the Russian Federation: analysis of the data from 75 regions by G. R. Hachatryan, T. S. Teptsova, V. A. Lemeshko, N. Z. Musina

    Published 2019-01-01
    “…Фармакоэкономика…”
    Get full text
    Article
    Save to List
    Saved in:
  17. 97
    Cost-effectiveness analysis of acalabrutinib in treatment of patients with relapsed/refractory form of mantle cell lymphoma who previously received at least one line of therapy

    Cost-effectiveness analysis of acalabrutinib in treatment of patients with relapsed/refractory form of mantle cell lymphoma who previously received at least one line of therapy by S. K. Zyryanov, I. N. Dyakov

    Published 2024-08-01
    “…Фармакоэкономика…”
    Get full text
    Article
    Save to List
    Saved in:
  18. 98
    DRUGS PROVIDED TO BREAST CANCER PATIENTS WITHIN THE STATE PROGRAMS OF DRUG SUPPLY

    DRUGS PROVIDED TO BREAST CANCER PATIENTS WITHIN THE STATE PROGRAMS OF DRUG SUPPLY by M. V. Avxentyeva, V. I. Bogin, E. V. Derkach, V. V. Omelyanovskiy, M. B. Stenina, A. V. Tarakanov, M. Yu. Frolov

    Published 2016-12-01
    “…Фармакоэкономика…”
    Get full text
    Article
    Save to List
    Saved in:
  19. 99
    Increasing the medico-economic efficiency of preventive counseling for patients with arterial hypertension and behavioral risk factors for non-communicable diseases

    Increasing the medico-economic efficiency of preventive counseling for patients with arterial hypertension and behavioral risk factors for non-communicable diseases by O. L. Zadvornaya, A. N. Pishchita

    Published 2021-10-01
    “…Фармакоэкономика…”
    Get full text
    Article
    Save to List
    Saved in:
  20. 100
    PATIENTS WITH NEUROLOGICAL DISEASES: RATIONALE FOR PHARMACOECONOMIC EVALUATION OF COST OPTIMIZATION FOR MANAGEMENT WITH NEURON-SPECIFIC PROTEINS ASSESSMENT AS MARKERS OF INCREASED BLOOD-BRAIN-BARRIER PERMEABILITY

    PATIENTS WITH NEUROLOGICAL DISEASES: RATIONALE FOR PHARMACOECONOMIC EVALUATION OF COST OPTIMIZATION FOR MANAGEMENT WITH NEURON-SPECIFIC PROTEINS ASSESSMENT AS MARKERS OF INCREASED... by D. V. Blinov

    Published 2015-03-01
    “…Фармакоэкономика…”
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: